Martingale Asset Management’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.51M Buy
15,830
+3,600
+29% +$328K 0.04% 446
2026
Q1
$1.18M Sell
12,230
-640
-5% -$64K 0.03% 455
2025
Q4
$1.25M Sell
12,870
-149
-1% -$12.8K 0.03% 425
2025
Q3
$926K Sell
13,019
-110
-0.8% -$7.33K 0.02% 498
2025
Q2
$785K Buy
13,129
+298
+2% +$16.3K 0.02% 519
2025
Q1
$673K Buy
12,831
+300
+2% +$16.9K 0.02% 546
2024
Q4
$689K Buy
12,531
+2
+0% +$105 0.02% 549
2024
Q3
$630K Buy
12,529
+1,671
+15% +$77.1K 0.01% 579
2024
Q2
$477K Buy
10,858
+100
+0.9% +$4.25K 0.01% 608
2024
Q1
$473K Buy
10,758
+87
+0.8% +$3.85K 0.01% 629
2023
Q4
$507K Buy
10,671
+30
+0.3% +$1.26K 0.01% 611
2023
Q3
$472K Buy
10,641
+100
+0.9% +$4.65K 0.01% 620
2023
Q2
$503K Buy
10,541
+2,101
+25% +$94.8K 0.01% 611
2023
Q1
$332K Buy
8,440
+501
+6% +$18.2K 0.01% 693
2022
Q4
$225K Buy
7,939
+5
+0.1% +$143 ﹤0.01% 772
2022
Q3
$239K Buy
7,934
+5
+0.1% +$174 ﹤0.01% 750
2022
Q2
$270K Buy
7,929
+219
+3% +$7.85K ﹤0.01% 756
2022
Q1
$346K Buy
7,710
+400
+5% +$18.5K 0.01% 706
2021
Q4
$338K Buy
+7,310
New +$295K ﹤0.01% 720
2020
Q4
Sell
-17,203
Closed -$368K 970
2020
Q3
$368K Buy
+17,203
New +$386K ﹤0.01% 870

Other funds holding IRMD

Martingale Asset Management's IRMD Position: Q2 2026 in Review

Martingale Asset Management increased its iRadimed (IRMD) stake by 29% in Q2 2026, buying an estimated $328K and bringing the position to 15,830 shares worth $1.51M. The position accounts for 0.04% of the portfolio, ranked #446.

Martingale Asset Management first reported a position in IRMD in Q3 2020 and has held it in 20 quarters since. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Martingale Asset Management held 15,830 shares of iRadimed worth $1.51M as of Q2 2026.
  • Martingale Asset Management bought 3,600 iRadimed shares in Q2 2026, an estimated $328K.
  • iRadimed made up 0.04% of Martingale Asset Management's portfolio in Q2 2026, its #446 holding.
  • Martingale Asset Management first reported a position in iRadimed in Q3 2020 and has held it in 20 quarters since.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.